share_log

Biodexa Pharmaceuticals | POS AM: Post-effective amendment to a registration statement that is not immediately effective upon filing

SEC announcement ·  Apr 30 18:10
Summary by Futu AI
Biodexa Pharmaceuticals PLC, a clinical-stage biopharmaceutical company, has announced the completion of several significant corporate transactions and the filing of a post-effective amendment to a registration statement with the SEC. The company has entered into a License and Collaboration Agreement with Emtora Biosciences for the exclusive rights to eRapa, a pharmaceutical formulation of rapamycin, and has also acquired the compound tolimidone from Adhera Therapeutics, Inc. Additionally, Biodexa has completed an underwritten public offering, raising approximately $6.0 million. These strategic moves aim to strengthen Biodexa's product pipeline and financial position. The company's securities are traded on the NASDAQ Capital Market under the symbol 'BDRX.'
Biodexa Pharmaceuticals PLC, a clinical-stage biopharmaceutical company, has announced the completion of several significant corporate transactions and the filing of a post-effective amendment to a registration statement with the SEC. The company has entered into a License and Collaboration Agreement with Emtora Biosciences for the exclusive rights to eRapa, a pharmaceutical formulation of rapamycin, and has also acquired the compound tolimidone from Adhera Therapeutics, Inc. Additionally, Biodexa has completed an underwritten public offering, raising approximately $6.0 million. These strategic moves aim to strengthen Biodexa's product pipeline and financial position. The company's securities are traded on the NASDAQ Capital Market under the symbol 'BDRX.'
Helpful
Not Helpful

This announcement is a separate document:

Doc 1

Doc 2

The information provided by Futu AI is automatically generated by third-party artificial intelligence (AI) software based on news content. It is only available to users located outside of China mainland.


The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.